Global Advanced Drug Delivery Systems Market Size (2024 - 2029)

Advanced Drug Delivery Systems Market Analysis

The advanced drug delivery systems (ADDS) market is expected to register a CAGR of 5.3% during the forecast period (2022-2027).

The COVID-19 pandemic had positively impacted the market's growth rate. Several studies emphasize how ADDS will help develop improved delivery systems (dosage forms) of existing therapeutic agents. For instance, in June 2020, the Chalmers University of Technology in Sweden, the University of Gothenburg, and AstraZeneca started new pivotal research combining many promising concepts to investigate a nasal spray mRNA vaccine against COVID-19. The team was working on a biomimetic nanoparticle that contains both immune enhancers and a targeting protein to investigate design principles for nasal immunization. The Chalmers Innovation Office, the Chalmers Area of Advance Health Engineering, the Swedish Foundation for Strategic Research, and the Swedish Research Council contributed to the initiative.

Additionally, in April 2020, Bioavanta-Bosti developed a 48-hour manufacturing process using its Novochizol chitosan polysaccharide nanotechnology to encapsulate APIs or biologics for localized delivery and sustained release intra-pulmonary drug delivery formulations, which are suitable for treating COVID-19 patients. Bioavanta-Bosti also reported in 2020 that it is looking for collaborations with drug developers and clinical researchers to produce a repurposed medicine or new molecular or biological entity formulations to treat severe COVID-19 infection in the lungs. ADDS has aided in exploring new insights to identify untapped areas for future targeted distribution, and it is quickly gaining traction in the pharmaceutical sector and academic institutions. Thus, COVID-19 has had a significant impact on the growth of the market.

Furthermore, the factors driving this market's growth include the development of new drugs and biologics; advancements in understanding human biology and diseases; and increased R&D spending.

Advancements in several biology-oriented initiatives have created a unique opportunity to better understand the molecular effects of human diseases and develop novel drugs and biologics based on these factors. The recently discovered advanced drug delivery systems include lipid, protein, and polymer technologies with better lipid distribution in the body, preventing drug degradation due to the external environment and reducing the rate of drug clearance. Advanced drugs and biologics have higher efficiency with a smaller dosage of drugs. Hence, they must be supported with advanced drug delivery systems to gain maximum efficacy.

In addition to the drugs and biologics, the drug-eluting implants have the potential to provide uninterrupted treatment and a reduction in drug dosage (hence a less frequent need for dosing). The advanced sustained release systems help target intestinal infections and others. The trend toward self-injection devices and the rapidly growing pipeline of biologics/biosimilars and auto-injectors have also recently emerged as an important class of medical devices. Many companies are focusing on the launch of new products that will contribute to market growth. For instance, in December 2020, Agile Therapeutics, Inc., commercially launched Twirla (levonorgestrel and Ethinyl estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch in the United States. Additionally, in February 2022, Nu Gen Medical Devices Inc. delivered a purchase order from a Taiwanese medical distributor, Shin-Ya Biotechnology Co., Ltd., for its InsuJet needleless injection system. This is part of a multi-year sales and distribution agreement with a minimum commitment of CDN 100,000 over the first two years, with future commitments for the remaining three years of the agreement to be finalized in due course. Such agreements are also contributing to the growth of the market.

Likewise, Duocap (capsule-in-a-capsule), electrocapsule, and light-up delivery monitoring technology (LDMT) are some of the controlled and targeted oral drug delivery systems that provide a new way of formulating poorly soluble compounds and monitoring the release rate of drugs. Advanced drug delivery systems are being developed to resolve solubility problems and make the drugs more lipid-soluble. Thus, this enables them to easily cross lipid barriers in the body, eventually preventing external issues, such as photodegradation and pH changes, from affecting the drug and further achieving the desired concentration at the desired location to provide the maximum therapeutic effect. Thus, these developments are expected to positively impact the market's growth.

However, product recalls of advanced drug delivery products and challenges in nanomedicine-based drug delivery may hinder the growth of the market.

Advanced Drug Delivery Systems Industry Segmentation

As per the scope of the report, advanced drug delivery systems are improved methods for delivering the drug molecule to the targeted site in a more controlled manner. These methods are being developed to improve the efficacy ratio of the currently available drugs. Delivering drugs at a controlled rate, slow and targeted delivery for onsite drug release and absorption is the basis for developing advanced drug delivery systems. The Advanced Drug Delivery Systems Market is segmented by Type (Oral Drug Delivery System, Injection-based Drug Delivery System, Inhalation/Pulmonary Drug Delivery System, Transdermal Drug Delivery System, Transmucosal Drug Delivery System, Carrier-based Drug Delivery System, and Other Types), Application (Cardiovascular Diseases, Oncology, Urology, Diabetes, Central Nervous System, Ophthalmology, Infections, Other Applications), Technology (Prodrug, Implants, and Intrauterine Devices, Targeted Drug Delivery, Polymeric Drug Delivery, and Other Technologies), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 countries across major global regions.